Author(s):

Vibeke Strand, Jennifer Sloane Lazar, Michael C Nivens, Jingdong Chao, Stefano Fiore, Angelika Giannelou, Lita Araujo, and Jerome Msihid

Abstract or description:

The poster reports the patient reported outcomes from the SAPHYR study. Patients treated with sarilumab 200mg Q2W + 14-week GC had clinically meaningful and robust improvement in patient reported outcomes compared to patients receiving placebo + 52-week GC.

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Topics

Patient reported outcomes from a Randomized Controlled Phase 3 Trial of Sarilumab in Polymyalgia Rheumatica

A US Patient Perspective on the Diagnosis and Burden of AxSpA

Safety of a JAKi Across 15,000 Patient-Years of Data

Bimekizumab-Treated Patients with Active Psoriatic Arthritis Showed Sustained Achievement of Minimal Disease Activity and Remission: Up to 2-Year Results from Two Phase 3 Studies

Bimekizumab Maintained Efficacy Responses Through 52 Weeks in Patients with Active Psoriatic Arthritis: Results from Two Phase 3 Studies

Do you get our email newsletter?